IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v81y2007i2-3p376-384.html
   My bibliography  Save this article

Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals

Author

Listed:
  • Andersson, Karolina
  • Bergstrom, Gina
  • Petzold, Max G.
  • Carlsten, Anders

Abstract

No abstract is available for this item.

Suggested Citation

  • Andersson, Karolina & Bergstrom, Gina & Petzold, Max G. & Carlsten, Anders, 2007. "Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals," Health Policy, Elsevier, vol. 81(2-3), pages 376-384, May.
    • Handle: RePEc:eee:hepoli:v:81:y:2007:i:2-3:p:376-384
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168-8510(06)00170-9
    Download Restriction: Full text for ScienceDirect subscribers only
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Puig-Junoy, Jaume, 2004. "Incentives and pharmaceutical reimbursement reforms in Spain," Health Policy, Elsevier, vol. 67(2), pages 149-165, February.
    2. Fattore, Giovanni & Jommi, Claudio, 1998. "The new pharmaceutical policy in Italy," Health Policy, Elsevier, vol. 46(1), pages 21-41, October.
    3. David Granlund & Niklas Rudholm & Magnus Wikström, 2006. "Fixed budgets as a cost containment measure for pharmaceuticals," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(1), pages 37-45, March.
    4. Drummond, Michael & Jonsson, Bengt & Rutten, Frans, 1997. "The role of economic evaluation in the pricing and reimbursement of medicines," Health Policy, Elsevier, vol. 40(3), pages 199-215, June.
    5. Morgan, Steven G. & Agnew, Jonathan D. & Barer, Morris L., 2004. "Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia," Health Policy, Elsevier, vol. 68(3), pages 299-307, June.
    6. Ljungkvist, Mats-Olof & Andersson, David & Gunnarsson, Bo, 1997. "Cost and utilisation of pharmaceuticals in Sweden," Health Policy, Elsevier, vol. 41(Supplemen), pages 55-69, September.
    7. Rainer Winkelmann, 2004. "Co‐payments for prescription drugs and the demand for doctor visits – Evidence from a natural experiment," Health Economics, John Wiley & Sons, Ltd., vol. 13(11), pages 1081-1089, November.
    8. Schneeweiss, Sebastian & Schoffski, Oliver & Selke, Gisbert W, 1998. "What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?," Health Policy, Elsevier, vol. 44(3), pages 253-260, June.
    9. Liu, Shuen-Zen & Romeis, James C., 2004. "Changes in drug utilization following the outpatient prescription drug cost-sharing program--evidence from Taiwan's elderly," Health Policy, Elsevier, vol. 68(3), pages 277-287, June.
    10. Ghislandi, Simone & Krulichova, Iva & Garattini, Livio, 2005. "Pharmaceutical policy in Italy: towards a structural change?," Health Policy, Elsevier, vol. 72(1), pages 53-63, April.
    11. Giuliani, Giovanni & Selke, Gisbert & Garattini, Livio, 1998. "The German experience in reference pricing," Health Policy, Elsevier, vol. 44(1), pages 73-85, April.
    12. Garattini, Livio & Tediosi, Fabrizio, 2000. "A comparative analysis of generics markets in five European countries," Health Policy, Elsevier, vol. 51(3), pages 149-162, April.
    13. Andersson, Karolina & Petzold, Max Gustav & Sonesson, Christian & Lonnroth, Knut & Carlsten, Anders, 2006. "Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures?: Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002," Health Policy, Elsevier, vol. 79(2-3), pages 231-243, December.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Leemore Dafny & Christopher Ody & Matt Schmitt, 2017. "When Discounts Raise Costs: The Effect of Copay Coupons on Generic Utilization," American Economic Journal: Economic Policy, American Economic Association, vol. 9(2), pages 91-123, May.
    2. Georg Heinze & Milan Hronsky & Berthold Reichardt & Christoph Baumgärtel & Marcus Müllner & Anna Bucsics & Wolfgang Winkelmayer, 2015. "Potential Savings in Prescription Drug Costs for Hypertension, Hyperlipidemia, and Diabetes Mellitus by Equivalent Drug Substitution in Austria: A Nationwide Cohort Study," Applied Health Economics and Health Policy, Springer, vol. 13(2), pages 193-205, April.
    3. Granlund, David, 2010. "Price and welfare effects of a pharmaceutical substitution reform," Journal of Health Economics, Elsevier, vol. 29(6), pages 856-865, December.
    4. Guhl, Dennis & Stargardt, Tom & Schneider, Udo & Fischer, Katharina E., 2016. "Dispensing behaviour of pharmacies in prescription drug markets," Health Policy, Elsevier, vol. 120(2), pages 190-197.
    5. Maurus Rischatsch & Maria Trottmann & Peter Zweifel, 2013. "Generic substitution, financial interests, and imperfect agency," International Journal of Health Economics and Management, Springer, vol. 13(2), pages 115-138, June.
    6. Skaltsas, Leonora N. & Vasileiou, Konstantinos Z., 2015. "Patients’ perceptions of generic drugs in Greece," Health Policy, Elsevier, vol. 119(11), pages 1406-1414.
    7. Burapadaja, Siriporn & Kawasaki, Naohito & Charumanee, Suporn & Ogata, Fumihiko, 2007. "Effects of essential medicines on cardiovascular products available for the market in Thailand," Health Policy, Elsevier, vol. 84(1), pages 67-74, November.
    8. Chong, Chee Ping & March, Geoff & Clark, Alice & Gilbert, Andrew & Hassali, Mohamed Azmi & Bahari, Mohd Baidi, 2011. "A nationwide study on generic medicines substitution practices of Australian community pharmacists and patient acceptance," Health Policy, Elsevier, vol. 99(2), pages 139-148, February.
    9. Michael Berger & Markus Pock & Miriam Reiss & Gerald Röhrling & Thomas Czypionka, 2023. "Exploring the effectiveness of demand-side retail pharmaceutical expenditure reforms," International Journal of Health Economics and Management, Springer, vol. 23(1), pages 149-172, March.
    10. Timonen, Johanna & Karttunen, Pekka & Bengtström, Marina & Ahonen, Riitta, 2009. "The impact of generic substitution on the turnover and gross margin of pharmaceutical companies a survey 1 year and 5 years after the introduction of generic substitution in Finland," Health Policy, Elsevier, vol. 92(2-3), pages 116-123, October.
    11. Cristina Zerbini & Donata Tania Vergura & Beatrice Luceri, 2017. "Consumers? intention to buy generic drugs: Evidences from the Italian setting," MERCATI & COMPETITIVIT?, FrancoAngeli Editore, vol. 2017(1), pages 159-176.
    12. Miguel, Lorena San & Augustin, Uta & Busse, Reinhard & Knai, Cécile & Rubert, Gloria & Sihvo, Sinikka & Baeten, Rita, 2014. "Recognition of pharmaceutical prescriptions across the European Union: A comparison of five Member States’ policies and practices," Health Policy, Elsevier, vol. 116(2), pages 206-213.
    13. Pernilla J Bjerkeli & Anna K Jönsson & Eva Lesén & Ann-Charlotte Mårdby & Karolina Andersson Sundell, 2016. "Refill Adherence in Relation to Substitution and the Use of Multiple Medications: A Nationwide Population Based Study on New ACE-Inhibitor Users," PLOS ONE, Public Library of Science, vol. 11(5), pages 1-15, May.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Andersson, Karolina & Petzold, Max Gustav & Sonesson, Christian & Lonnroth, Knut & Carlsten, Anders, 2006. "Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures?: Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002," Health Policy, Elsevier, vol. 79(2-3), pages 231-243, December.
    2. Burapadaja, Siriporn & Kawasaki, Naohito & Charumanee, Suporn & Ogata, Fumihiko, 2007. "Effects of essential medicines on cardiovascular products available for the market in Thailand," Health Policy, Elsevier, vol. 84(1), pages 67-74, November.
    3. Lopez-Casasnovas, Guillem & Puig-Junoy, Jaume, 2000. "Review of the literature on reference pricing," Health Policy, Elsevier, vol. 54(2), pages 87-123, November.
    4. Garattini, Livio & Cornago, Dante & De Compadri, Paola, 2007. "Pricing and reimbursement of in-patent drugs in seven European countries: A comparative analysis," Health Policy, Elsevier, vol. 82(3), pages 330-339, August.
    5. Ghislandi, Simone & Krulichova, Iva & Garattini, Livio, 2005. "Pharmaceutical policy in Italy: towards a structural change?," Health Policy, Elsevier, vol. 72(1), pages 53-63, April.
    6. Bergstrom, Gina & Karlberg, Ingvar, 2007. "Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden: Assessment of models for decentralized financing of subsidies from a management perspective," Health Policy, Elsevier, vol. 81(2-3), pages 358-367, May.
    7. Chiara Bonassi & Laura Magazzini & Fabio Pammolli & Massimo Riccaboni & Nicola Carmine Salerno, 2007. "Il prezzo di riferimento nel quadro regolatorio del mercato farmaceutico," Working Papers CERM 04-2007, Competitività, Regole, Mercati (CERM).
    8. Kalo, Zoltan & Muszbek, Noemi & Bodrogi, Jozsef & Bidlo, Judit, 2007. "Does therapeutic reference pricing always result in cost-containment?: The Hungarian evidence," Health Policy, Elsevier, vol. 80(3), pages 402-412, March.
    9. Mousnad, Mohamed Awad & Shafie, Asrul Akmal & Ibrahim, Mohamed Izham, 2014. "Systematic review of factors affecting pharmaceutical expenditures," Health Policy, Elsevier, vol. 116(2), pages 137-146.
    10. Garattini, Livio & Tediosi, Fabrizio, 2000. "A comparative analysis of generics markets in five European countries," Health Policy, Elsevier, vol. 51(3), pages 149-162, April.
    11. Livio Garattini & Katelijne Vooren, 2015. "Safety and Quality of Generic Drugs: A Never Ending Debate Fostered by Economic Interests?," Applied Health Economics and Health Policy, Springer, vol. 13(1), pages 3-4, August.
    12. Livio Garattini & Alessandro Curto & Katelijne Vooren, 2015. "Western European markets for biosimilar and generic drugs: worth differentiating," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(7), pages 683-687, September.
    13. Patrizio Armeni & Claudio Jommi & Monica Otto, 2016. "The simultaneous effects of pharmaceutical policies from payers’ and patients’ perspectives: Italy as a case study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 963-977, November.
    14. Galina Besstremyannaya, 2014. "Heterogeneous effect of coinsurance rate on healthcare costs: generalized finite mixtures and matching estimators," Discussion Papers 14-014, Stanford Institute for Economic Policy Research.
    15. George France & Francesco Taroni & Andrea Donatini, 2005. "The Italian health‐care system," Health Economics, John Wiley & Sons, Ltd., vol. 14(S1), pages 187-202, September.
    16. Katelijne Vooren & Alessandro Curto & Livio Garattini, 2015. "Biosimilar Versus Generic Drugs: Same But Different?," Applied Health Economics and Health Policy, Springer, vol. 13(2), pages 125-127, April.
    17. Yue-Chune Lee & Ming-Chin Yang & Yu-Tung Huang & Chien-Hsiang Liu & Sun-Bing Chen, 2006. "Impacts of Cost Containment Strategies on Pharmaceutical Expenditures of the National Health Insurance in Taiwan, 1996–2003," PharmacoEconomics, Springer, vol. 24(9), pages 891-902, September.
    18. Lagravinese, Raffaele & Paradiso, Massimo, 2012. "Corruption and health expenditure in Italy," MPRA Paper 43215, University Library of Munich, Germany.
    19. Pieter Dylst & Steven Simoens, 2011. "Does the Market Share of Generic Medicines Influence the Price Level?," PharmacoEconomics, Springer, vol. 29(10), pages 875-882, October.
    20. Schreyögg, Jonas & Henke, Klaus-Dirk & Busse, Reinhard, 2004. "Managing pharmaceutical regulation in Germany: Overview and economic assessment," Discussion Papers 2004/6, Technische Universität Berlin, School of Economics and Management.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:81:y:2007:i:2-3:p:376-384. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.